Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.60 |
| ▸ | PPARA | Q07869 | 16/20 | 0.60 |
| ▸ | PPARD | Q03181 | 9/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL1834451 | 0.88 | PPARA (0.63) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543205 | 0.83 | PPARG (0.62) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL27654978 | 0.81 | PPARA (0.76) | PPARGPPARAPPARD | |
| SCHEMBL5394822 | 0.80 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5383883 | 0.79 | PPARA (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5383887 | 0.79 | PPARA (0.84) | PPARGPPARAPPARD | |
| SCHEMBL27674846 | 0.79 | PPARA (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5375774 | 0.79 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL543437 | 0.78 | PGR (0.66) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL7532753 | 0.77 | PPARG (0.80) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212057-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2012-07-03 | — | — | US | disclosed |
| EP-1414439-B1 | NOVEL PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILA HEALTHCARE LTD (IN) | 2011-05-04 | — | — | EP | disclosed |
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | CADILLA HEALTHCARE LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | LIPC, CETP, PNLIP | PPARG 217/4885PPARA 126/4885PPARD 133/4885 |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | PPARG 129/4885PPARA 68/4885PPARD 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.